Hepatocellular carcinoma in non-cirrhotic liver: A reappraisal

Digestive and Liver Disease

Volumn 42, Issue 5, 2010, Pages 341-347

  Trevisani, Franco ^a   Frigerio, Marta ^a   Santi, Valentina ^a   Grignaschi, Alice ^a   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chronic hepatitis; Fatty liver; Hepatocellular carcinoma; Liver cirrhosis; Liver fibrosis

Indexed keywords

ALPHA FETOPROTEIN; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; SEX HORMONE; SORAFENIB;

AGE DISTRIBUTION; ALCOHOL ABUSE; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ECHOGRAPHY; ENVIRONMENTAL EXPOSURE; GENE MUTATION; GENOTOXICITY; HEALTH SURVEY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SHORT SURVEY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREJUDICE; YOUNG ADULT;

EID: 77951628838     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.09.002     Document Type: Short Survey

References (105)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Okuda K., Nakashima T., Kojiro M., et al. Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989, 97:140-146.
3. Kew M.C., Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984, 4:136-146.
4. Calvet X., Bruix J., Brú C., et al. Natural history of hepatocellular carcinoma in Spain. J Hepatol 1990, 10:311-317.
5. Stroffolini T., Sagnelli E., Mariano A., et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998, 29:944-952.
6. Trevisani F., D'Intino P.E., Caraceni P., et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995, 75:2220-2232.
7. Craig J.R., Klatt E.C., Yu M. Role of cirrhosis and the development of HCC: evidence from histologic studies and large population studies. Etiology, pathology, and treatment of hepatocellular carcinoma in North America 1991, 177-190. Gulf Publishing, Houston. E. Tabor, A.M. Di Bisceglie, R.H. Purcell (Eds.).
8. Nzeako U.C., Goodman Z.D., Ishak K.G. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996, 105:65-75.
9. National Coordination Group of Pathology of Liver Cancer Relationship between hepatocellular carcinoma, liver cirrhosis, and hepatitis B: a pathological study. Natl Med J China 1982, 62:257-261.
10. Smalley S.R., Moertel C.G., Hilton J.F., et al. Hepatoma in the noncirrhotic liver. Cancer 1988, 62:1414-1424.
11. Grazi G.L., Cescon M., Ravaioli M., et al. Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 2003, 17:119-129.
12. Chang C.H., Chau G.Y., Lui W.Y., et al. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004, 139:320-325.
13. Shimada M., Rikimaru T., Sugimachi K., et al. The importance of hepatic resection for hepatocellular carcinoma originating from nonfibrotic liver. J Am Coll Surg 2000, 191:531-537.
14. Kakar S., Burgart L.J., Batts K.P., et al. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol 2005, 18:1417-1423.
15. El-Serag H.B., Davila J.A. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology 2004, 39:798-803.
16. Okuda K., Nakashima T., Sakamoto K., et al. Hepatocellular carcinoma arising in noncirrhotic and highly cirrhotic livers: a comparative study of histopathology and frequency of hepatitis B markers. Cancer 1982, 49:450-455.
17. Kalayci C., Johnson P.J., Davies S.E., et al. Hepatitis B virus related hepatocellular carcinoma in the non-cirrhotic liver. J Hepatol 1991, 12:54-59.
18. Grando-Lemaire V., Guettier C., Chevret S., et al. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 1999, 31:508-513.
19. Bralet M.P., Régimbeau J.M., Pineau P., et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000, 32:200-204.
20. Chen M.F., Tsai H.P., Jeng L.B., et al. Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg 2003, 27:443-447.
21. Kumar M., Kumar R., Hissar S.S., et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India. J Gastroenterol Hepatol 2007, 22:1104-1111.
22. Taura K., Ikai I., Hatano E., et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery 2007, 142:685-694.
23. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006, 6:674-687.
24. Liu C.J., Chen B.F., Chen P.J., et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J Infect Dis 2006, 194:594-599.
25. Yuen M.F., Tanaka Y., Shinkai N., et al. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotype B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008, 57:98-102.
26. Guo X., Jin Y., Qian G., et al. Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China. J Hepatol 2008, 49:718-725.
27. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-181.
28. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
29. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-430.
30. Ray R.B., Meyer K., Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000, 271:197-204.
31. Park J.S., Yang J.M., Min M.K. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 2000, 267:581-587.
32. Sakamuro D., Furukawa T., Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995, 69:3893-3896.
33. El-Refaie A., Savage K., Bhattacharya S., et al. HCV-associated hepatocellular carcinoma without cirrhosis. J Hepatol 1996, 24:277-285.
34. Liang T.J., Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004, 127:S62-71.
35. De Mitri M.S., Poussin K., Baccarani P., et al. HCV-associated liver cancer without cirrhosis. Lancet 1995, 345:413-415.
36. Makiyama A., Itoh Y., Kasahara A., et al. Characteristic of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004, 101:1616-1622.
37. Ikeda M., Fujiyama S., Tanaka M., et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005, 40:148-156.
38. Ikeda K., Marusawa H., Osaki Y., et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med 2007, 146:649-656.
39. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-154.
40. Adami H.O., Hsing A.W., Mclaughlin J.K., et al. Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer 1992, 51:898-902.
41. London W.T., McGlynn K.A. Liver cancer. Cancer epidemiology and prevention 1996, 772-793. Oxford University Press, New York. D. Schottenfeld, J.F. Fraumeni (Eds.).
42. Reiter E., Zentek J., Razzazi E. Review on sample preparation strategies and methods used for the analysis of aflatoxins in food and feed. Mol Nutr Food Res 2009, 53:508-524.
43. Qian G.S., Ross R.K., Yu M.C., et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994, 3:3-10.
44. Ming L., Thorgeirsson S.S., Gail M.H., et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002, 36:1214-1220.
45. Lipshutz G.S., Brennan T.V., Warren R.S. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg 2002, 195:713-718.
46. Turlin B., Juguet F., Moirand R., et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995, 22:446-450.
47. Sorrentino P., D'Angelo S., Ferbo U., et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009, 50:351-357.
48. Kew M.D. Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic patients. Hepatology 1990, 11:1086-1087.
49. Deugnier Y.M., Guyader D., Crantock L., et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993, 104:228-234.
50. Zhou H., Fischer H.P. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol 1998, 22:742-748.
51. Andersson C., Bjersing L., Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med 1996, 240:195-201.
52. Nakayama M., Okamoto Y., Morita T., et al. Promoting effect of citrulline in hepatocarcinogenesis: possible mechanism in hypercitrullinemia. Hepatology 1990, 11:819-823.
53. Conti J.A., Kemeny N. Type Ia glycogenosis associated with hepatocellular carcinoma. Cancer 1992, 69:1320-1322.
54. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993, 152:S63-70.
55. Rudnick D.A., Perlmutter D.H. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005, 42:514-521.
56. Le Bail B., Bioulac-Sage P., Arnoux R., et al. Late recurrence of a hepatocellular carcinoma in a patient with incomplete Alagille syndrome. Gastroenterology 1990, 99:1514-1516.
57. Bauman M.E., Pound D.C., Ulbright T.M. Hepatocellular carcinoma arising in congenital hepatic fibrosis. Am J Gastroenterol 1994, 89:450-451.
58. Takayasu K., Muramatsu Y., Moriyama N., et al. Radiological study of idiopathic Budd-Chiari syndrome complicated by hepatocellular carcinoma. A report of four cases. Am J Gastroenterol 1994, 89:249-253.
59. Nzeako U.C., Goodman Z.D., Ishak K.G. Hepatocellular carcinoma and nodular regenerative hyperplasia: possible pathogenetic relationship. Am J Gastroenterol 1996, 91:879-884.
60. Johnson F.L., Feagler J.R., Lerner K.G., et al. Association of androgenic anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972, 16:1273-1276.
61. Farrell G.C., Joshua D.E., Uren R.F., et al. Androgen-induced hepatoma. Lancet 1975, 22:430-432.
62. Neuberger J., Forman D., Doll R., et al. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986, 292:1355-1357.
63. Forman D., Vincent T.J., Doll R. Cancer of the liver and the use of oral contraceptives. Br Med J 1986, 292:1357-1361.
64. Irey N.S., Manion W.C., Taylor H.B. Vascular lesions in women taking oral contraceptives. Arch Pathol 1970, 73:386-394.
65. Zucman-Rossi J., Jeannot E., Nhieu J.T., et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524.
66. Bioulac-Sage P., Rebouissou S., Thomas C., et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748.
67. Hassan M.M., Spitz M.R., Thomas M.B., et al. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 2009, 50:334-341.
68. Gruner B.A., DeNapoli T.S., Andrews W., et al. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol 1998, 20:274-278.
69. INK4 (MTS1) Gene Occur in a subset of patients with hepatocellular carcinoma. Hepatology 1997, 25:1376-1381.
70. Tannapfel A., Wittekind C. Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 2002, 440:345-352.
71. Chiappini F., Gross-Goupil M., Saffroy R., et al. Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis 2004, 25:541-547.
72. Togni R., Bagla N., Muiesan P., et al. Microsatellite instability in hepatocellular carcinoma in non-cirrhotic liver in patients older than 60 years. Hepatol Res 2009, 39:266-273.
73. Xu L., Huang L., Li B.K., et al. Clinicopathologic features and long-term outcomes of Chinese patients with hepatocellular carcinoma in non-cirrhotic liver. Dig Surg 2008, 25:376-382.
74. Capussotti L., Muratore A., Amisano M., et al. Liver resection for large-size hepatocellular carcinomas in 47 non-cirrhotic patients-no mortality and long-term survival. Hepatogastroenterology 2006, 53:768-772.
75. Okamura N., Yoshida M., Shibuya A., et al. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathol Int 2005, 55:724-731.
76. Kassahun W.T., Hauss J. Management of combined hepatocellular and cholangiocarcinoma. Int J Clin Pract 2008, 62:1271-1278.
77. Castells L., Vargas V., Comas P., et al. Hepatocellular carcinoma: clinical aspects, diagnosis, and survival in 140 cases. Med Clin (Barc) 1993, 100:441-446.
78. Vivarelli M., Cavallari A., Bellusci R., et al. Ruptured hepatocellular carcinoma: an important cause of spontaneous haemoperitoneum in Italy. Eur J Surg 1995, 161:881-886.
79. Akriviadis E.A. Hemoperitoneum in patients with ascites. Am J Gastroenterol 1997, 92:567-575.
80. Makuuchi M., Mori T., Gunven P., et al. Safety of hemihepatic vascular occlusion during resection of the liver. Surg Gynecol Obstet 1987, 164:155-158.
81. Hu R.H., Lee P.H., Yu S.C., et al. Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996, 120:23-29.
82. Bismuth H., Chiche L., Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg 1995, 19:35-41.
83. Lubrano J., Huet E., Tsilividis B., et al. Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse. World J Surg 2008, 32:104-109.
84. Bège T., Le Treut Y.P., Hardwigsen J., et al. Prognostic factors after resection for hepatocellular carcinoma in nonfibrotic or moderately fibrotic liver. A 116-case European series. J Gastrointest Surg 2007, 11:619-625.
85. Sasaki Y., Imaoka S., Masutani S., et al. Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. Surgery 1992, 112:515-521.
86. Poon R.T., Fan S.T., Lo C.M., et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000, 18:1094-1101.
87. Nagasue N., Ono T., Yamanoi A., et al. Prognostic factor and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001, 88:515-522.
88. Dupont-Bierre E., Compagnon P., Raoul J.L., et al. Resection of hepatocellular carcinoma in noncirrhotic liver: analysis of risk factors for survival. J Am Coll Surg 2005, 201:663-670.
89. Laurent C., Blanc J.F., Nobili S., et al. Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005, 201:656-662.
90. Lang H., Sotiropoulos G.C., Brokalaki E.I., et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 2007, 205:27-36.
91. Rayya F., Harms J., Bartels M., et al. Results of resection and transplantation for hepatocellular carcinoma in cirrhosis and noncirrhosis. Transplant Proc 2008, 40:933-935.
92. Sotiropoulos G.C., Bockhorn M., Sgourakis G., et al. R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis. Dig Dis Sci 2008, August [Epub ahead of print].
93. Edeline J., Raoul J.L., Vauleon E., et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009, 15:713-716.
94. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
95. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
96. Craig J.R., Peters R.L., Edmondson H.A., et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer 1980, 46:372-379.
97. Pinna A.D., Iwatsuki S., Lee R.G., et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 1997, 26:877-883.
98. Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002, 17:401-405.
99. Ruffin M.T. Fibrolamellar hepatoma. Am J Gastroenterol 1990, 85:577-581.
100. Ringe B., Wittekind C., Weimann A., et al. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet 1992, 175:299-305.
101. Nagorney D.M., Adson M.A., Weiland L.H., et al. Fibrolamellar hepatoma. Am J Surg 1985, 149:113-119.
102. Haas J.E., Muczynski K.A., Krailo M., et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer 1989, 64:1082-1095.
103. Katzenstein H.M., Krailo M.D., Malogolowkin M.H., et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer 2003, 97:2006-2012.
104. Kakar S., Chen X., Ho C., et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol 2009, 22:134-141.
105. Houben K.W., McCall J.L. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transplant Surg 1999, 5:91-95.